73results about "Endopeptidase" patented technology

The present invention relates to an inhibitory polypeptide for use in treating and / or preventing a transmembrane serine protease (TMPRSS) and / or neutrophil elastase mediated disease in a subject, wherein said inhibitory polypeptide comprises an amino acid sequence of SEQ ID NO:1 or an amino acid sequence at least 70% identical thereto. The present invention further relates to polynucleotides, host cells, devices, kits, and uses related thereto.

The present invention provides non-naturally occurring cystine knot peptides (CKPs) that bind VEGF-A. In addition, methods of using non-naturally occurring CKPs that bind VEGF-A are provided, including diagnostic and therapeutic compositions and methods. Non-natural CKPs that bind low-density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Aspects of the present disclosure relate to novel medical compositions and methods of using same. In certain aspects, the disclosure relates to methods preventing acute kidney injury in a patient associated with increased amount of protein in the urine (e.g. albuminuria). In certain embodiments, the disclosure provides methods of preventing or treating acute kidney injury in a patient receiving a nephrotoxic drug, by administration of a reversible endocytosis inhibitor.

This disclosure provides an alpha-1 antitrypsin (AAT) polypeptide as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, and methods of producing the AAT polypeptide and method of using the AAT polypeptide in therapy.

The invention discloses application of an alpha-amylase / subtilisin inhibitor LASI gene in improvement of drought resistance and salt resistance of crops. The nucleotide sequence of the Ligusticum wallichii LASI gene is as shown in SEQ ID NO. 1; transgenic arabidopsis thaliana plants are obtained through genetic engineering and transgenic identification methods, the drought resistance and the salt resistance of transgenic and wild type arabidopsis thaliana are analyzed through growth indexes and biochemical indexes, and LASI transgenic arabidopsis thaliana with the drought resistance and the salt resistance is successfully obtained. The invention provides a new gene source for cultivating crops with stronger drought resistance and salt tolerance by utilizing a gene engineering technology.

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

Use of a fructose disaccharide or fructooligosaccharide, for increasing protein production in Bifidobacterium longum subsp longum.

Among other things, polypeptides are disclosed that inhibit or suppress the activity of kallikrein-related proteases and are therefore useful for treating diseases and conditions associated with dysregulated kallikrein-related protease activity. Pharmaceutical compositions and methods of treatment using the polypeptides and pharmaceutical compositions are also provided.

The invention relates to methods of assessing liver disease in a subject by detecting one or more single-nucleotide polymorphisms (SNPs) of the subject and correlating the detected SNPs to the liver disease. The methods may also include a step of implementing a treatment decision, such as monitoring the subject for signs of liver disease, administering a therapeutic agent to the subject, liver transplant, or combinations thereof. The invention also relates to computing devices for assessing liver disease in a subject.

This disclosure provides alpha-1 antitrypsin (AAT) polypeptides as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, methods for producing the AAT polypeptide, and methods for using the AAT polypeptide in therapy.

The present disclosure provides methods and compositions for treating autoimmune and inflammatory conditions, including systemic lupus erythematosus and antiphospholipid syndrome.Certain aspects of the present disclosure relate to methods for treating autoimmune or inflammatory conditions, comprising administering a composition comprising a therapeutically effective amount of NAPc2 or NAPc2 / proline.Further aspects include pharmaceutical compositions comprising NAPc2 or NAPc2 / proline, and optionally one or more additional anti-inflammatory agents.

The invention discloses a preparation method and application of a PSA-ACT compound recombinant protein. The preparation method comprises the following steps: obtaining gene segments of recombinant PSA and ACT proteins; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation, transfection, induction and fermentation broth separation and purification operation on the recombinant plasmid to obtain recombinant PSA and ACT proteins; then activating PSA recombinant protein by using metalloproteinase, and then mixing ACT with the activated PSA to obtain a mixture containing the PSA, ACT and a PSA-ACT compound; and finally, purifying by using an ion exchange chromatography technology and a hydrophobic chromatography technology in sequence to obtain the high-purity and high-activity PSA-ACT compound. According to the method, the spontaneous reaction of ACT and activated PSA is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, and the recombinant protein can be produced on a large scale; the PSA-ACT recombinant protein prepared by the method disclosed by the invention has very strong immunoreactivity.

Provided are systems and polypeptide complexes that combine a scaffold protein module with various effect modules, enabling comprehensive and versatile control at the protein, RNA, and DNA levels. Further, provided their uses in regulation of gene expression and the potential usage in the treatment of diseases.

The present invention relates to extracts of bacteria of the genus Sphingomonas, compositions comprising at least one bacterium of the genus Sphingomonas or said extracts, their uses, and their implementation in cosmetic methods.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

This disclosure provides an alpha-1 antitrypsin (AAT) polypeptide as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, and methods of producing the AAT polypeptide and method of using the AAT polypeptide in therapy.

Wound healing is a process by which these wounds on the skin of a subject heal and eventually close. When the injured surface is large, becomes infected, or in patients with poor healing capacity such as diabetics or the elderly or bedridden patients, then wound healing can be prolonged and lead to chronic ulceration and further complications with even limb loss or increased morbidity and mortality. This invention is directed to a topical formulation for promoting wound healing, and wound dressings and bandages comprising the same.

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

The application relates to the field of agricultural biotechnology, in particular to an LMSerpinb1 gene and application thereof. A locusta migratoria serpinb1 gene is cloned, and the locusta migratoria mortality and the gene expression amount change of the target gene in the locusta migratoria are detected through the method of mixed feeding of the locusta migratoria with metarhizium anisopliae, so that the role of the locusta migratoria in the metarhizium anisopliae infection is verified, and a foundation for further clarifying the action mechanism of Serpin is laid.

Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

A peptide library comprising a plurality of different peptides. The peptides each comprise an amino acid sequence encoded by a nucleotide sequence consisting of the sequence of SEQ ID NO: 14. The nucleotide sequence has been modified by replacing a nucleotide sequence consisting of the 43rd base thymine to the 93rd base thymine with a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1. The peptide library has a diversity of at least 1 × 105. In SEQ ID NO: 1, each of the 1st Xaa to the 5th Xaa, the 7th Xaa, the 9th Xaa, and the 10th Xaa in each peptide is independently any amino acid other than cysteine and proline. Each of the 6th Xaa and the 8th Xaa in each peptide is independently any amino acid other than cysteine. The 11th Xaa in each peptide is independently selected from tyrosine, serine, phenylalanine, leucine, and threonine. The 12th Xaa in each peptide is independently selected from asparagine, aspartic acid, leucine, lysine, glutamine, alanine, and glutamic acid.

In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and / or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and / or a heavy chain constant region, wherein the antibody inhibits complement activation.

The present invention provides methods and compositions for reducing internalization and / or trafficking of tau in neuronal cells comprising contacting the cells with an effective amount of an LRP1 and / or SorLA antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of an LRP1 and / or SorLA antagonist.

In some aspects, the disclosure relates to compositions and methods that are useful for treating inflammatory disorders and conditions. In some embodiments, the disclosure provides recombinant adeno-associated virus (rAAV) vectors and particles encoding a transgene that expresses a Myxomavirus serine proteinase inhibitor (Serp) protein (e.g., Serp-1) and methods for treating inflammatory disorders using the same.

Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Featured are cells and methods of use thereof for modulating an antigen-specific immune response in a subject. The cells comprise a set of transgenes comprising two or more of PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASG or FasL, Ccl21 or Ccl21b, MfgeS and Serpin B9 or Spi6, that shield the cells from immune surveillance (ie. “cloaking genes”). The cells can be used to induce immune tolerance to an antigen (e.g., a donor alloantigen or a self-antigen), or to induce an immune response to (e.g., induce the production of antibodies directed against) a non-self antigen.

To provide a target binding peptide.SOLUTION: A target-binding peptide obtained by a method comprising the steps of: bringing a peptide contained in a peptide library into contact with a target molecule; recovering a peptide bound to the target molecule; and preparing the recovered peptide by gene recombination.SELECTED DRAWING: None

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

The present invention discloses polypeptides useful, inter alia, for inhibiting or suppressing the activity of trypsin-associated proteases, and thus treating diseases and conditions involving a disorder of trypsin-associated protease activity. Pharmaceutical compositions and methods of treatment using the polypeptides and pharmaceutical compositions are also provided.